Differential reactivity of bovine lymphocytes to species of Brucella

R Smith1, J C Kapatsa, S J Sherwood

  • 1Department of Veterinary Pathology, Texas A&M University, College Station 77843-4463.

Insights

Bovine lymphocytes showed varied reactivity to Brucella species. Susceptibility to brucellosis correlated with cross-reactivity to Brucella suis and Brucella melitensis in these cattle.

Area of Science:

  • Veterinary Immunology
  • Bacteriology
  • Animal Health

Background:

  • Brucellosis is a significant zoonotic disease affecting cattle globally.
  • Understanding the bovine immune response to Brucella species is crucial for disease control.
  • Previous studies have indicated variability in lymphocyte responses within cattle populations.

Purpose of the Study:

  • To investigate the in vitro reactivity patterns of bovine lymphocytes against four Brucella species.
  • To determine if lymphocyte reactivity correlates with natural resistance or susceptibility to brucellosis in cattle.

Main Methods:

  • Thymidine uptake assays were performed on lymphocytes from cattle naturally resistant or susceptible to brucellosis.
  • Long-term cultured lymphocytes and freshly obtained blood mononuclear cells were utilized.
  • Lymphocyte reactivity was assessed against four Brucella species: B. abortus, B. canis, B. suis, and B. melitensis.

Main Results:

  • Three distinct patterns of lymphocyte reactivity to Brucella species were identified.
  • A statistically significant correlation was observed between susceptibility to brucellosis and lymphocyte cross-reactivity with B. suis (P < 0.01).
  • A strong correlation was found between brucellosis susceptibility and lymphocyte cross-reactivity with B. melitensis (P < 0.001).

Conclusions:

  • Bovine lymphocyte reactivity to Brucella species is heterogeneous.
  • Specific patterns of lymphocyte cross-reactivity, particularly with B. suis and B. melitensis, are associated with susceptibility to brucellosis in cattle.
  • These findings may inform diagnostic strategies and vaccine development for bovine brucellosis.